Drug Profile
Volrustomig - AstraZeneca
Alternative Names: MEDI-5752; PD-1/CTLA-4 bispecific mAb; PD-l/CTLA-4 DuetMabLatest Information Update: 22 Dec 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca; Daiichi Sankyo Company; MedImmune
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cervical cancer; Malignant-mesothelioma; Non-small cell lung cancer; Squamous cell cancer
- Phase II Adenocarcinoma; Biliary cancer; Liver cancer; Solid tumours
- Phase I Renal cell carcinoma; Sarcoma
Most Recent Events
- 22 Dec 2023 Phase-III clinical trials in Malignant mesothelioma (Combination therapy, Late-stage disease, Inoperable/Unresectable) in Canada, South Korea, Switzerland, Taiwan, Turkey, United Kingdom (IV) (NCT06097728)
- 22 Dec 2023 700368284: CTP push: Update mesothelioma trial initiation in KDM, dev table and HE
- 14 Dec 2023 Phase-III clinical trials in Squamous cell cancer (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA, South Korea, Taiwan (Parenteral) (NCT06129864)